HS patient registry and sample storage study
Part of Infections, Skin clinical trials.
This study enrolls people with hidradenitis suppurativa (HS) to better understand the condition over time and store optional health information and samples. Being in the registry may help researchers learn about patterns in HS and support future research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 10 or older
- Have a confirmed diagnosis of HS by a clinician experienced in diagnosing HS
- Be able to give informed consent (and have a guardian consent if needed)
- You (or your legal guardian) must agree and be willing to follow the study steps
- If you cannot consent or no guardian is available, you cannot join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the physical and biological (body-related) characteristics of hidradenitis suppurativa. It may help researchers understand the condition better and improve future care.
This study tracks the daily experiences of people living with hidradenitis suppurativa to learn more about their symptoms and treatment patterns. By participating, you help doctors better understand this condition, which could lead to improved care and support.
This study collects and stores skin samples and related health information from people seen in OSU Dermatology clinics. It helps researchers better understand skin conditions and may lead to new treatments in the future.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
This study tests a new drug called LAD328 for hidradenitis suppurativa (HS), a chronic skin condition with painful lumps and abscesses. The trial is looking for adults with moderate-to-severe HS who haven't responded well to antibiotics to see if this new treatment can help reduce symptoms.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.